Rationally designed minimized TbpB confers broad protection against meningococcal infection
Islam, E. A.; Fegan, J. E.; Cole, G. B.; Calmettes, C.; Ng, D.; Au, N. Y. T.; Buckwalter, C. M.; Ahn, S. K.; Curran, D. M.; Caruso, L.-l.; Schryvers, A. B.; Moraes, T.; Gray-Owen, S.
Show abstract
Transferrin binding protein B (TbpB), an iron acquisition protein, has long been recognized as a promising vaccine candidate targeting the pathogenic Neisseria species, including Neisseria meningitidis, the cause of meningococcal disease, and Neisseria gonorrhoeae, the cause of gonorrhea. A challenge to the development of this protein as a vaccine immunogen is the extent of antigenic variability it exhibits, which complicates the selection of a single variant to elicit a broadly cross-protective immune response. We have utilized structure-informed antigen engineering to develop a minimized version of TbpB consisting of the proteins carboxy-terminal lobe with its variable surface loops removed. Here, we reveal the effectiveness of this "loopless C-lobe" as an independent immunogen, with structural characterization and stability studies to demonstrate its integrity, and murine immunization and challenge studies that establish its ability to elicit robust protective efficacy by using N. meningitidis invasive infection and nasopharyngeal colonization models. The breadth of protection provided, as measured by both in vitro analysis and cross-protection mouse challenge studies, indicate that a single loopless C-lobe elicits a broadly cross-protective immune response against the diverse panel of meningococcal strains tested, and that the cross-reactivity is superior to that offered by the intact TbpB or the native C-lobe. Together, this study demonstrates the utility of structure-informed antigen engineering towards the development of broadly efficacious protein-based vaccines. ImportanceSurface-exposed proteins on bacterial pathogens are enticing candidate vaccine targets, however their exposure to the immune system frequently leads to high levels of antigenic variation, a factor that complicates the development of broadly protective vaccines. Here, we undertake an antigen engineering approach to develop a minimized version of a surface lipoprotein, transferrin binding protein B, where variable regions of the protein have been removed to focus the immune response to conserved regions of this antigen. We combine structural studies and mouse infection models of Neisseria meningitidis, the cause of meningococcal disease, and Neisseria gonorrhoeae, the causative agent of gonorrhea, to reveal that our strategic minimizing of the protein immunogen focuses the immune response to extend the resulting breadth of cross-reactivity and cross-protection.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Soluble immune mediators orchestrate protective in vitro granulomatous responses across Mycobacterium tuberculosis complex lineages 94%
- Cell-autonomous targeting of arabinogalactan by host immune factors inhibits mycobacterial growth 94%
- A Live Attenuated Vaccine Model Confers Cross-Protective Immunity Against Different Species of Leptospira spp. 94%
Similar papers in this journal
- Capsular polysaccharide inhibits vaccine-induced O-antigen antibody binding and function across both classical and hypervirulent K2:O1 strains of Klebsiella pneumoniae 95%
- Structure selected RBM immunogens prime polyclonal memory responses that neutralize SARS-CoV-2 variants of concern 94%
- Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection 94%
Similar papers in this journal
- Spike-specific IgG4 generated post BNT162b2 mRNA vaccination is inhibitory when directly competing with functional IgG subclasses 95%
- BNT162b2 induced neutralizing and non-neutralizing antibody functions against SARSCoV-2 diminish with age 95%
- ChAdOx1 nCoV-19 (AZD1222) vaccine elicits monoclonal antibodies with potent cross-neutralizing activity against SARS-CoV-2 viral variants 94%
Similar papers in this journal
- Broad neutralization of SARS-CoV-2 variants, including omicron, following breakthrough infection with delta in COVID-19 vaccinated individuals 95%
- A bacteriophage-based, highly efficacious, needle and adjuvant-free, mucosal COVID-19 vaccine 95%
- An engineered receptor-binding domain improves the immunogenicity of multivalent SARS-CoV-2 vaccines 94%
Similar papers in this journal
- Parenteral Vaccination with recombinant EtpA glycoprotein impairs enterotoxigenic E. coli colonization 96%
- Vaccine-specific immune responses against Mycobacterium ulcerans infection in a low-dose murine challenge model 94%
- Broadly reactive human monoclonal antibodies targeting the pneumococcal histidine triad protein protect against fatal pneumococcal infection 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.